The headline EPS and revenue miss vs consensus is a negative surprise, but the guidance raise signals management sees underlying operational strength. Watch the earnings call for details on talc resolution timing and MedTech growth trajectory. The stock may open lower on the miss but could recover if the guidance raise is viewed as credible.
Price Chart
Executive Summary
JNJ reported Q3 2026 adjusted EPS of $2.59, a -11.2% miss vs consensus of $2.92, and revenue of $25.4B vs $26.43B consensus. GAAP EPS was $0.09 due to a $5.5B litigation charge for the proposed talc resolution. The company raised full-year 2026 adjusted EPS guidance by $0.06 to $11.10 midpoint and reported sales guidance to $101.2B midpoint, signaling confidence in operational momentum despite the headline miss.
Key Financial Metrics
Key Facts
- Q3 2026 adjusted EPS $2.59 vs consensus $2.92 (-11.2% miss)
- Q3 2026 reported sales $25.4B vs consensus $26.43B (-3.9% miss)
- GAAP EPS $0.09 reflects $5.5B litigation charge for proposed talc resolution
- Worldwide operational sales grew 6.0% YoY; adjusted operational sales grew 6.1%
- Innovative Medicine operational sales +7.9%; MedTech +2.5%
- Raised FY2026 adjusted EPS guidance to $11.05-$11.15 (midpoint $11.10, +2.9% YoY)
- Raised FY2026 reported sales guidance to $101.0B-$101.4B (midpoint $101.2B, +7.4% YoY)
- Free cash flow YTD estimated at $15.1B vs $14.2B prior year
- FDA approval of IMAAVY (nipocalimab) for wAIHA; FDA market authorization for OTTAVA robotic surgical system
Financial Impact
Q3 adjusted EPS miss of $0.33 vs consensus; revenue miss of ~$1.0B. Guidance raise partially offsets negative surprise. Talc litigation charge of $5.5B pre-tax is a one-time non-cash item.
Risk Factors
- Talc litigation resolution remains subject to court approval and could face challenges
- MedTech growth slowed to 2.5% operational, below historical trends
- STELARA biosimilar erosion continues (-54.4% YoY in Q3)
- Pulmonary Hypertension franchise declined 19.5% YoY on OPSUMIT/OPSYNVI weakness
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000200406-26-000189 |
| Document: a2026q3exhibit991.htm | 0000200406-26-000189 |
| Document: jnj-20261013.htm | 0000200406-26-000189 |
| Document: 0000200406-26-000189-index-headers.html | 0000200406-26-000189 |
| Document: 0000200406-26-000189-index.html | 0000200406-26-000189 |
| Document: 0000200406-26-000189.txt | 0000200406-26-000189 |
| 8-K Data (Synthetic) | 0000200406-26-000189 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $248.61 | awaiting T+60 | awaiting T+60 | $268.73 (+8.09%) |
Sep 30, 2026 28d ago | Court Ruling | $258.66 | awaiting T+60 | awaiting T+60 | $268.73 (+3.89%) |
Sep 24, 2026 4w ago | Court Ruling | $271.22 | awaiting T+60 | awaiting T+60 | $268.73 (−0.92%) |
Sep 9, 2026 7w ago | Court Ruling | $266.35 | awaiting T+60 | awaiting T+60 | $268.73 (+0.89%) |
Aug 18, 2026 10w ago | Insider Cluster | $273.41 | awaiting T+60 | awaiting T+60 | $268.73 (−1.71%) |
Aug 14, 2026 10w ago | Insider Cluster | $262.37 | awaiting T+60 | awaiting T+60 | $268.73 (+2.42%) |
Aug 7, 2026 11w ago | Insider Cluster | $261.81 | awaiting T+60 | awaiting T+60 | $268.73 (+2.64%) |
Aug 7, 2026 11w ago | Court Ruling | $261.81 | awaiting T+60 | awaiting T+60 | $268.73 (−2.64%) |
Aug 4, 2026 12w ago | 8-K | $254.93 | awaiting T+60 | awaiting T+60 | $268.73 (+5.41%) |
Jul 22, 2026 14w ago | Court Ruling | $259.27 $255.56 | ▲ +1.43% | ▲ +4.83% | $268.73 (−3.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers